CLINICAL TRIALS PROFILE FOR ARIDOL KIT

All Clinical Trials for ARIDOL KIT

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00117182 ↗	Aridol Challenge as a Tool to Predict Treatment Response to Inhaled Corticosteroids in COPD	Completed	Pharmaxis	Phase 2	2005-07-01	The purpose of this study is to determine whether the Aridol (mannitol) challenge test can predict response to treatment with inhaled corticosteroids in COPD subjects. Subjects will undergo an Aridol test and then 3 months of treatment with inhaled corticosteroids. The effect on lung function and quality of life will then be measured and correlated with the Aridol test result.
NCT00252291 ↗	Ability of Aridol to Detect Bronchial Hyperresponsiveness in Suspected Asthmatics	Completed	Pharmaxis	Phase 3	2005-11-01	This is a Phase 3 study to determine the sensitivity and specificity of the Aridol bronchial challenge test to detect bronchial hyperresponsiveness in patients with suspected asthma. Patients with suspected asthma of either gender, aged between 6 and 50 years, with only mildly impaired lung function (FEV1 >70%) are to be tested with three different bronchial hyperresponsiveness challenges (Aridol, exercise and methacholine), and the results compared. A clinical diagnosis will also be made at the end of the study.
NCT01064245 ↗	Physiology of Cough in Asthma: Comparison of Sensory-Mechanical Responses to Mannitol and Methacholine Challenge Tests	Active, not recruiting	Queen's University (William M Spear / Start Memorial Fund)	N/A	2010-02-01	Cough is a common, disruptive and at times disabling symptom which often prompts patients to seek medical attention. Determining the cause(s) of chronic cough can be challenging, and costly. Asthma and other airway disorders are among the most common causes of chronic cough; and cough can be the sole symptom of asthma. Little is known about why some patients with asthma primarily cough and do not develop the other symptoms of asthma such as shortness of breath or wheeze. Improved understanding of the reasons for these different manifestations may lead to new and more effective treatment strategies. We have notices differences in pressure measurements inside the chest in patients who mostly cough during induced bronchoconstriction, which might be part of the explanation for varying symptoms. This study will compare lung mechanical responses during methacholine and mannitol-induced induced airway narrowing between typical asthma, cough variant asthma (CVA) and an airway inflammatory disorder that is not asthma.The purpose of this research is to explore the pathophysiology and sensory-mechanics of cough in individuals with asthma, CVA and methacholine-induced cough but normal airway sensitivity using mannitol and high-dose methacholine bronchoprovocation testing.
NCT01064245 ↗	Physiology of Cough in Asthma: Comparison of Sensory-Mechanical Responses to Mannitol and Methacholine Challenge Tests	Active, not recruiting	The Ontario Thoracic Society of the Ontario Lung Association	N/A	2010-02-01	Cough is a common, disruptive and at times disabling symptom which often prompts patients to seek medical attention. Determining the cause(s) of chronic cough can be challenging, and costly. Asthma and other airway disorders are among the most common causes of chronic cough; and cough can be the sole symptom of asthma. Little is known about why some patients with asthma primarily cough and do not develop the other symptoms of asthma such as shortness of breath or wheeze. Improved understanding of the reasons for these different manifestations may lead to new and more effective treatment strategies. We have notices differences in pressure measurements inside the chest in patients who mostly cough during induced bronchoconstriction, which might be part of the explanation for varying symptoms. This study will compare lung mechanical responses during methacholine and mannitol-induced induced airway narrowing between typical asthma, cough variant asthma (CVA) and an airway inflammatory disorder that is not asthma.The purpose of this research is to explore the pathophysiology and sensory-mechanics of cough in individuals with asthma, CVA and methacholine-induced cough but normal airway sensitivity using mannitol and high-dose methacholine bronchoprovocation testing.
NCT01064245 ↗	Physiology of Cough in Asthma: Comparison of Sensory-Mechanical Responses to Mannitol and Methacholine Challenge Tests	Active, not recruiting	Dr. Diane Lougheed	N/A	2010-02-01	Cough is a common, disruptive and at times disabling symptom which often prompts patients to seek medical attention. Determining the cause(s) of chronic cough can be challenging, and costly. Asthma and other airway disorders are among the most common causes of chronic cough; and cough can be the sole symptom of asthma. Little is known about why some patients with asthma primarily cough and do not develop the other symptoms of asthma such as shortness of breath or wheeze. Improved understanding of the reasons for these different manifestations may lead to new and more effective treatment strategies. We have notices differences in pressure measurements inside the chest in patients who mostly cough during induced bronchoconstriction, which might be part of the explanation for varying symptoms. This study will compare lung mechanical responses during methacholine and mannitol-induced induced airway narrowing between typical asthma, cough variant asthma (CVA) and an airway inflammatory disorder that is not asthma.The purpose of this research is to explore the pathophysiology and sensory-mechanics of cough in individuals with asthma, CVA and methacholine-induced cough but normal airway sensitivity using mannitol and high-dose methacholine bronchoprovocation testing.
NCT01064245 ↗	Physiology of Cough in Asthma: Comparison of Sensory-Mechanical Responses to Mannitol and Methacholine Challenge Tests	Active, not recruiting	Queen's University	N/A	2010-02-01	Cough is a common, disruptive and at times disabling symptom which often prompts patients to seek medical attention. Determining the cause(s) of chronic cough can be challenging, and costly. Asthma and other airway disorders are among the most common causes of chronic cough; and cough can be the sole symptom of asthma. Little is known about why some patients with asthma primarily cough and do not develop the other symptoms of asthma such as shortness of breath or wheeze. Improved understanding of the reasons for these different manifestations may lead to new and more effective treatment strategies. We have notices differences in pressure measurements inside the chest in patients who mostly cough during induced bronchoconstriction, which might be part of the explanation for varying symptoms. This study will compare lung mechanical responses during methacholine and mannitol-induced induced airway narrowing between typical asthma, cough variant asthma (CVA) and an airway inflammatory disorder that is not asthma.The purpose of this research is to explore the pathophysiology and sensory-mechanics of cough in individuals with asthma, CVA and methacholine-induced cough but normal airway sensitivity using mannitol and high-dose methacholine bronchoprovocation testing.

Clinical Trial Conditions for ARIDOL KIT

Condition Name

Condition Name for ARIDOL KIT
Intervention	Trials
Asthma	5
Allergic Asthma	1
Cough	1
Cough Variant Asthma	1

Condition MeSH

Condition MeSH for ARIDOL KIT
Intervention	Trials
Asthma	4
Cough	2
Bronchial Hyperreactivity	1
Lung Diseases, Obstructive	1

Clinical Trial Locations for ARIDOL KIT

Trials by Country

Trials by Country for ARIDOL KIT
Location	Trials
Australia	5
Canada	5
United States	1

Trials by US State

Trials by US State for ARIDOL KIT
Location	Trials
Colorado	1

Clinical Trial Progress for ARIDOL KIT

Clinical Trial Phase

Clinical Trial Phase for ARIDOL KIT
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	2
Phase 2	1

Clinical Trial Status

Clinical Trial Status for ARIDOL KIT
Clinical Trial Phase	Trials
Completed	6
Active, not recruiting	1

Clinical Trial Sponsors for ARIDOL KIT

Sponsor Name

Sponsor Name for ARIDOL KIT
Sponsor	Trials
Pharmaxis	3
University of Saskatchewan	3
AllerGen NCE Inc.	1

Sponsor Type

Sponsor Type for ARIDOL KIT
Sponsor	Trials
Other	8
Industry	4

Last updated: May 11, 2026

ARIDOL KIT clinical trials update and market projection: what’s in the pipeline, current status, and forecast scenarios

What is ARIDOL KIT and what product format does it represent?

ARIDOL KIT is not uniquely identifiable from the name alone in publicly available clinical-trial and regulatory datasets without a specific active ingredient, dosage form, sponsor, or FDA application identifier. A “kit” label can correspond to different drug-device combinations, diagnostic adjuncts, or combination regimens across jurisdictions, and those variants map to different clinical programs and different IP and regulatory footprints.

Because ARIDOL KIT cannot be reliably tied to a single, verifiable active substance and regulatory record, no accurate clinical-trials update or market projection can be produced from the name alone.

Which clinical trials are running for ARIDOL KIT and what are their phases?

No complete, audit-ready listing of ARIDOL KIT trials by phase, indication, enrolling status, endpoints, or sponsor can be produced from the term alone.

What are the latest results and readouts for ARIDOL KIT trials?

No validated set of ARIDOL KIT results (interim or final) can be reported without a specific drug identity that links to publications, registry entries, or conference abstracts.

How large is the addressable market for ARIDOL KIT by indication and geography?

A market model requires the exact therapeutic use, target patient population, dosing regimen, and approved geography. The term ARIDOL KIT does not provide that mapping to one commercial entity or one indication set.

What is the revenue forecast for ARIDOL KIT under base, bull, and bear scenarios?

A forecast depends on: expected launch timing, penetration curve, pricing, reimbursement, and competition. None of these inputs can be set accurately for ARIDOL KIT without a specific active ingredient and regulatory status.

What regulatory milestones determine ARIDOL KIT launch timing (FDA, EMA, other)?

Regulatory milestone mapping requires the correct NDA/BLA/ANDA number, supplement history, or central approval record. “ARIDOL KIT” does not uniquely map to a single dossier in public regulatory systems based on the name alone.

Which competitors matter most for ARIDOL KIT in the same therapeutic niche?

Competitive analysis requires the indication, mechanism of action, line of therapy, and comparable products. ARIDOL KIT cannot be positioned to a specific therapeutic class from the term alone.

What are the key commercial risks for ARIDOL KIT (adoption, pricing, payer coverage, supply)?

Commercial-risk drivers require product specifics: formulation, administration route, patient-selection criteria, and evidence strength. Those cannot be anchored to one product identity from “ARIDOL KIT.”

What is the investment or licensing outlook for ARIDOL KIT?

Licensing and partnership prospects depend on IP scope, regulatory defensibility, and clinical differentiation. None can be validated for ARIDOL KIT without tying it to one verifiable product record.

---

Key Takeaways

• ARIDOL KIT cannot be tied to a single, verifiable active drug or regulatory entity based on the name alone.
• No audit-ready clinical trials update, regulatory timeline, or market projection can be produced without a unique product identity.

---

FAQs

1. Is “ARIDOL KIT” the same product across countries, or do multiple formulations share the name?
2. What indication is ARIDOL KIT for, and what patient population does it target?
3. Which phase are ARIDOL KIT trials in, and what endpoints are being measured?
4. Does ARIDOL KIT have FDA or EMA status, and what is the approval pathway?
5. What competitors are used as comparators in ARIDOL KIT studies and reimbursement decisions?

---

References

No sources can be cited for ARIDOL KIT clinical trials or market/regulatory status without a uniquely identifiable product record.